VIDEO: Odevixibat well tolerated in progressive familial intrahepatic cholestasis

In this exclusive video, Richard Thompson, MD, PhD, discussed results from two abstracts presented at The Liver Meeting Digital Experience on using odevixibat in progressive familial intrahepatic cholestasis.Thompson, professor of molecular hepatology at King’s College London, reported that odevixibat was well tolerated in the phase 3 extension study. Results showed significant reductions in serum bile acids and pruritus that was maintained up to 48 weeks. He also described the side effect profile as ‘acceptable’.Read More

Share on facebook
Share on twitter
Share on linkedin